仙琚制药(002332) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for the first quarter was CNY 957,286,011.96, a decrease of 8.75% compared to CNY 1,049,027,960.34 in the same period last year[16] - Net profit attributable to shareholders of the listed company was CNY 133,111,920.61, an increase of 4.23% from CNY 127,713,332.35 year-on-year[16] - The net cash flow from operating activities reached CNY 69,164,061.26, a significant increase of 1,065.20% compared to CNY 5,935,810.00 in the previous year[16] - Total operating income for the period was 957,286,011.96 yuan, a decrease of 8.75% compared to 1,049,027,960.34 yuan in the same period last year[24] - Total operating costs decreased by 11.69% to 794,203,612.80 yuan from 898,974,340.09 yuan in the previous year[24] - Sales expenses decreased by 30.09%, a reduction of 95.19 million yuan, mainly due to a decrease in marketing expenses[33] - Financial expenses decreased by 123.96%, a reduction of 7.29 million yuan, mainly due to decreased interest expenses and increased interest income[33] - Other income increased by 375.81% year-on-year, an increase of CNY 0.8857 million, mainly due to an increase in other operating income[39] - Other expenses decreased by 83.9% year-on-year, a decrease of CNY 4.6737 million, mainly due to the suspension of operations at Haisheng Company in the previous year[39] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,917,547,289.10, reflecting a growth of 2.66% from CNY 6,738,173,286.59 at the end of the previous year[16] - Total liabilities amounted to CNY 1.2664 billion, an increase from CNY 1.2307 billion at the beginning of the year[43] - Total equity remained stable at CNY 2.6512 billion, unchanged from the previous period[43] - Equity attributable to shareholders of the listed company was CNY 5,604,999,529.18, up 2.70% from CNY 5,457,448,911.92 year-on-year[16] - Other receivables increased by 42.24% compared to the beginning of the year, an increase of 29.92 million yuan, mainly due to the increase in other temporary payments[18] - Accounts receivable increased by 42.6% compared to the beginning of the year, an increase of CNY 1.5397 million, mainly due to an increase in accepted bills received during the collection of payments[39] - Prepayments increased by 219.14% compared to the beginning of the year, an increase of CNY 48.6421 million, primarily due to an increase in prepayments according to contracts[39] Cash Flow - Cash flow from operating activities was 69,164,061.26 yuan, significantly up from 5,935,810.00 yuan in the same period last year[26] - Cash flow from investment activities showed a net outflow of 33,293,931.92 yuan, compared to a net outflow of 63,740,310.49 yuan in the previous year[26] - Cash flow from financing activities was not detailed in the report[26] - Cash paid for debt repayment decreased by 82.2%, down CNY 53,713,400.00, attributed to reduced cash outflows for debt repayment[4] - Cash paid for dividends, profits, or interest decreased by 72.8%, down CNY 2,337,200.00, mainly due to reduced interest payments[4] - Cash received from borrowings decreased by 100% year-on-year, a decrease of CNY 110.8 million, mainly due to a reduction in borrowings in the current period[53] Shareholder Information - Zhejiang Xianju Pharmaceutical Co., Ltd. reported a total of 213,221,808 shares held by the largest shareholder, Xianju County State-owned Assets Investment Group Co., Ltd.[54] - The second largest shareholder, Li Qinjian, holds 23,307,900 shares, representing a significant stake in the company[54] - The company has a diverse shareholder base, with notable investments from various funds, including 19,649,937 shares held by China Construction Bank's fund[54] - The financial report indicates a strong interest from institutional investors, with several funds holding over 11 million shares each[54] Future Outlook - The first quarter report for 2023 is expected to provide insights into the company's performance and future outlook[57] - The company is focusing on expanding its market presence and enhancing its product offerings in the pharmaceutical sector[58] - Future guidance will likely include projections for revenue growth and strategic initiatives in research and development[58] - The company is actively pursuing new technologies and product innovations to strengthen its competitive position[58] - Market expansion strategies are being discussed to capture a larger share of the pharmaceutical market[58] - The company is considering potential mergers and acquisitions to enhance its growth trajectory and market reach[58] Other Financial Metrics - Investment income decreased by 133.6% year-on-year, down CNY 4,708,900.00, primarily due to reduced profits from associated companies[4] - Credit impairment losses increased by 47.36%, up CNY 2,829,200.00, mainly due to increased provisions for bad debts[4] - The basic and diluted earnings per share remained at CNY 0.13, unchanged from the previous year[16] - R&D expenses for the period were 41,335,925.30 yuan, down from 57,373,399.37 yuan in the previous year[24] - Other comprehensive income increased by 251.39%, an increase of 14.44 million yuan, mainly due to foreign currency translation differences[18] - Non-current asset disposal loss was CNY -1.5384 million[52] - Government subsidies recognized in the current period amounted to CNY 1.8443 million[52]